BRAF V600E mutational status in pediatric thyroid cancer

Area of Science:

• Oncology
• Genetics
• Pediatric Medicine

Background:

• Clinical outcomes for pediatric papillary thyroid carcinoma (PTC) differ from adults, with unclear reasons.
• Previous research suggests lower BRAF(V600E) mutation prevalence in pediatric PTC, but data is limited.
• The relationship between BRAF(V600E) mutation and outcomes in pediatric PTC remains largely unknown.

Purpose of the Study:

• To determine the prevalence of the BRAF(V600E) mutation in pediatric PTC.
• To investigate the association between BRAF(V600E) mutation status and clinical characteristics, including progression-free survival (PFS).

Main Methods:

• BRAF(V600E) mutational status was analyzed in 27 pediatric PTC patients (age < 22) using restriction fragment length polymorphism (RFLP).
• Statistical analysis correlated mutation status with patient/tumor characteristics and PFS.

Main Results:

• BRAF(V600E) mutation was found in 63% of pediatric PTC cases, with a higher incidence in males (P = 0.033).
• No correlation was observed between BRAF(V600E) status and disease extent, tumor size, invasion, or margin status.
• Ten-year PFS was 55.5% for BRAF(V600E)-positive patients versus 70.0% for negative patients (P = 0.48); overall survival was 100%.

Conclusions:

• Pediatric PTC exhibits BRAF(V600E) mutation rates comparable to adult PTC.
• BRAF(V600E) mutation is associated with male gender but not with more aggressive disease features in pediatric PTC.
• Differences in PTC disease course between children and adults are not primarily driven by the BRAF(V600E) mutation.